References
[1]
World Health Organization. The epidemiology and impact of dementia:
current state and future trends. 2015. Available at:
http://www.who.int/mental_health/neurology/
dementia/dementia_thematicbrief_ epidemiology.pdf. [Accessed: 3
January 2020]
[2] NHS Digital. Recorded Dementia Diagnosis Data December 2019.
Available at:
https://digital.nhs.uk/data-and-information/publications/statistical/recorded-dementia-diagnoses/december-2019.
[Accessed: 20 January 2020]
[3] National Institute for Health and Care Excellence. Dementia:
assessment, management and support for people living with dementia and
their carers. 2018. Available at:
www.nice.org.uk/guidance/ng97.
[Accessed: January 20 2020]
[4] Department of Health and Social Care. Living well with dementia:
A National Dementia Strategy.2009. Available at:
https://www.gov.uk/government/publications/living-well-with-dementia-a-national-dementia-strategy.
[Accessed: January 20 2020]
[5] National Institute for Health and Care Excellence. NICE Quality
and Outcomes Framework indicator. The percentage of patients diagnosed
with dementia whose care plan has been reviewed in a face-to-face review
in the preceding 12 months. 2015. Available at:
https://www.nice.org.uk/standards-and-indicators/qofindicators/nm107.
[Accessed: June 10 2020]
[6] Szczepura, A., Wild, D., Khan, A.J., Owen, D.W., Palmer, T.,
Muhammad, T., Clark, M.D. & Bowman, C. Antipsychotic prescribing in
care homes before and after launch of a national dementia strategy: an
observational study in English institutions over a 4-year period. BMJ
Open 2016; 6(9):e009882.
[7] Sultana, J., Fontana, A., Giorgianni, F., Pasqua, A., Cricelli,
C., Spina, E., Gambassi, G., Ivanovic, J., Ferrajolo, C., Molokhia, M.,
Ballard, C., Sharp, S., Sturkenboom, M. & Trifirò, G.. The Effect of
Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons
with Dementia in the United Kingdom and Italy: A Population-Based Study.
CNS Drugs 2016, 30(11):1097-1109.
[8] Stocks, S.J., Kontopantelis, E., Webb, R.T., Avery, A.J., Burns,
A. & Ashcroft, D.M. Antipsychotic Prescribing to Patients Diagnosed
with Dementia Without a Diagnosis of Psychosis in the Context of
National Guidance and Drug Safety Warnings: Longitudinal Study in UK
General Practice. Drug Safety 2017. 40(8):679-692.
[9] Barry, H.E., Cooper, J.A., Ryan, C., Passmore, A.P., Robinson,
A.L., Molloy, G.J., Darcy, C.M., Buchanan, H. & Hughes, C.M.
Potentially Inappropriate Prescribing Among People with Dementia in
Primary Care: A Retrospective Cross-Sectional Study Using the Enhanced
Prescribing Database. Journal of Alzheimer’s Disease 2016;
52(4):1503-1513.
[10] OpenPrescribing.net (2020). EDM DataLab, University of Oxford.
Available: OpenPrescribing.net. [Accessed: 4 February 2020].
[11] NHS Digital. Prescriptions Dispensed in the Community-
Statistics for England, 2006-2016, National Statistics. Available at:
https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community/prescriptions-dispensed-in-the-community-statistics-for-england-2006-2016-pas.
[Accessed: 25 February 2020].
[12] NHS Digital . Practice level prescribing data: more
information. Available:
https://digital.nhs.uk/data-and-information/areas-of-interest/prescribing/practice-level-prescribing-in-england-a-summary/practice-level-prescribing-data-more-information.
[Accessed: 4 February 2020].
[13] Prescribing and Medicines Team, NHS Digital Prescriptions
Dispensed in the Community- England 2006 to 2016, National Statistics.
Available at:
https://files.digital.nhs.uk/publication/s/o/pres-disp-com-eng-2006-16-rep.pdf
[Accessed: 25 February 2020].
[14] Royal Pharmaceutical Society of Great Britain. British National
Formulary 78. Royal Pharmaceutical Society; 2019.
[15] Ministry of Housing & Communities & Local Government (2015).
National Statistics: English indices of deprivation (2015). Available
at:
https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015.
[Accessed: 27 February 2020].
[16] Office for National Statistics (2019). Population projections
for clinical commissioning groups and NHS regions: Table 3. Available
at:
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/datasets/clinicalcommissioninggroupsinenglandtable3.
[Accessed 29 February 2020].
[17] Office for National Statistics. CPI Index 06.1.1:
Pharmaceutical Products 2015=100, England. Available at:
https://www.ons.gov.uk/economy/inflationandpriceindices/datasets/consumerpriceindices.
[Accessed: 14 January 2020].
[18] NHS Digital 2018, Quality and Outcomes Framework, Achievement,
prevalence and exceptions data - 2017-18 [PAS]. England. Available
at:
https://digital.nhs.uk/data-and-information/publications/statistical/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data/2017-18.
[Accessed: 11 March 2020].
[19] Office for National Statistics Series DR_15 Mortality
Statistics; Deaths registered in England and Wales in 2015. Key
Non-Parliamentary Papers Central Government. Available at:
http://publicinformationonline.com/download/138417. [Accessed:
10 March 2020].
[20] Department of Health. Prime Minister’s challenge on dementia
2020. Available at:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/414344/pm-dementia2020.pdf
[Accessed: 9 June 2020].
[21] National Institute for Health and Care Excellence. National
Institute for Health and Care Excellence. Dementia: supporting people
with dementia and their carers in health and social care. London.
Available: https://www.nice.org.uk/guidance/cg42. [Accessed: 10
March 2020]
[22] National Institute for Health and Care Excellence . Donepezil,
galantamine, rivastigmine and memantine for the treatment of Alzheimer’s
disease. London. Available at:
www.nice.org.uk/guidance/ta217.
[28 January 2020].
[23] Walker, V.M., Davies, N.M., Kehoe, P.G. & Martin, R.M. (2018).
What is the impact of regulatory guidance and expiry of drug patents on
dementia drug prescriptions in England? A trend analysis in the Clinical
Practice Research Datalink. Alzheimer’s Research & Therapy
2018;10(1):51.
[24] Cooper, C., Lodwick, R., Walters, K., Raine, R., Manthorpe, J.,
Iliffe, S. & Petersen, I. (2016). Observational cohort study:
deprivation and access to anti-dementia drugs in the UK. Age and Ageing
45(1)148-154.
[25] Public Health England (2017). Chapter 4: Inequality and Health.
Health Profile for England. Available at:
https://www.gov.uk/government/publications/health-profile-for-england/chapter-5-inequality-in-health.
[Accessed: 5 March 2020]
[26] Baker, C. Health inequalities: Income deprivation and
north/south divides. House of Commons Library. Available at:
https://commonslibrary.parliament.uk/insights/health-inequalities-income-deprivation-and-north-south-divides/
[Accessed 2 March 2020].
[27] Banerjee, S. The use of antipsychotic medication for people
with dementia: Time for action. Department of Health and Social Care.
[Accessed 20 March 2020]
[28] National Institute for Health and Care Excellence (2014).
Psychosis and schizophrenia in adults: prevention and management.
London. Available at:
https://www.nice.org.uk/guidance/cg178/resources/psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-35109758952133.
[Accessed 19 March 2020]
[29] Louise, C., Olivier, C., Maryse, L.M., Pierre, A.G., Jonathan,
F., Nicolas, S., Regis, B. & Benjamin, R. (2015). Off-Label Prescribing
of Antipsychotics in Adults, Children and Elderly Individuals: A
Systematic Review of Recent Prescription Trends. Current Pharmaceutical
Design 2015; 21(23): 3280-3297.